ORIC Oric Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ORIC

Price (delayed)

$13.72

Market cap

$1.42B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.32

Enterprise value

$1.38B

?
Relative Growth: Rel. Growth: 10
Relative Strength: Rel. Strength: 84
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 9

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-114, a brain penetrant inhibitor that selectively targets ...

Highlights
The EPS has increased by 30% year-on-year and by 6% since the previous quarter
Oric Pharmaceuticals's equity has increased by 18% YoY but it has decreased by 8% QoQ
The quick ratio has declined by 20% since the previous quarter and by 18% year-on-year
ORIC's net income is down by 3.8% since the previous quarter and by 2.3% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.oricpharma.com
Peers: OLMA OMER VIVS ORMP

Key stats

What are the main financial stats of ORIC

ORIC stock price

How has the Oric Pharmaceuticals stock price performed over time
Intraday
-0.22%
1 week
6.11%
1 month
31.17%
1 year
39.57%
YTD
67.73%
QTD
26.69%

Financial performance

How have Oric Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$156.14M
Net income
-$140.35M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 4.3% year-on-year and by 4.2% since the previous quarter
ORIC's net income is down by 3.8% since the previous quarter and by 2.3% year-on-year

Price vs fundamentals

How does ORIC's price correlate with its fundamentals

Growth

What is Oric Pharmaceuticals's growth rate over time

Valuation

What is Oric Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.73
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 30% year-on-year and by 6% since the previous quarter
The stock's P/B is 96% more than its 5-year quarterly average of 1.9 and 38% more than its last 4 quarters average of 2.7
Oric Pharmaceuticals's equity has increased by 18% YoY but it has decreased by 8% QoQ

Efficiency

How efficient is Oric Pharmaceuticals business performance
Oric Pharmaceuticals's return on invested capital has increased by 38% YoY and by 3.2% QoQ
The return on equity is up by 32% year-on-year
The ROA is up by 29% year-on-year

Dividends

What is ORIC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ORIC.

Financial health

How did Oric Pharmaceuticals financials performed over time
The quick ratio has declined by 20% since the previous quarter and by 18% year-on-year
The company's current ratio fell by 19% QoQ and by 18% YoY
ORIC's debt is 100% smaller than its equity
Oric Pharmaceuticals's equity has increased by 18% YoY but it has decreased by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.